Nivolumab immunotherapy helps patients with advanced bladder cancer

Posted by on June 5, 2016 4:41 pm
Categories: health

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug’s target, according to clinical trial results.

Leave a Reply

Your email address will not be published. Required fields are marked *